Rhythm Pharmaceuticals (RYTM) Non-Current Assets (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Assets for 10 consecutive years, with $12.1 million as the latest value for Q3 2025.
- On a quarterly basis, Non-Current Assets fell 48.03% to $12.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $59.6 million, a 37.33% decrease, with the full-year FY2024 number at $18.1 million, down 26.16% from a year prior.
- Non-Current Assets was $12.1 million for Q3 2025 at Rhythm Pharmaceuticals, roughly flat from $12.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $31.4 million in Q1 2022 to a low of $9.9 million in Q2 2021.
- A 5-year average of $21.6 million and a median of $23.2 million in 2024 define the central range for Non-Current Assets.
- Peak YoY movement for Non-Current Assets: soared 262.88% in 2021, then crashed 50.76% in 2025.
- Rhythm Pharmaceuticals' Non-Current Assets stood at $21.1 million in 2021, then soared by 33.63% to $28.2 million in 2022, then fell by 13.34% to $24.5 million in 2023, then dropped by 26.16% to $18.1 million in 2024, then crashed by 33.2% to $12.1 million in 2025.
- Per Business Quant, the three most recent readings for RYTM's Non-Current Assets are $12.1 million (Q3 2025), $12.1 million (Q2 2025), and $17.4 million (Q1 2025).